Clene Inc Stock Performance
| CLNN Stock | USD 4.17 0.16 3.99% |
The firm shows a Beta (market volatility) of 0.0191, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Clene's returns are expected to increase less than the market. However, during the bear market, the loss of holding Clene is expected to be smaller as well. At this point, Clene Inc has a negative expected return of -0.29%. Please make sure to confirm Clene's skewness, and the relationship between the total risk alpha and day median price , to decide if Clene Inc performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Clene Inc has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fragile performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Actual Historical Performance (%)
One Day Return 3.99 | Five Day Return (9.54) | Year To Date Return (29.08) | Ten Year Return (97.84) | All Time Return (97.84) |
Last Split Factor 1:20 | Last Split Date 2024-07-11 |
1 | BioMedNewsBreaks Clene Inc. Management to Present at the H.C. Wainwright 26th Annual Global Investment Conference | 09/03/2024 |
2 | Clene Announces Closing of 7.3 Million Registered Direct Offering and Concurrent Private Placements and Amendment of Debt Facility | 10/01/2024 |
3 | IBN Coverage Clene Announces Series of Direct Offerings, Concurrent Private Placements | 10/02/2024 |
4 | IBN Coverage Clene Closes on Direct Offering, Concurrent Private Placements Totaling 7.3M | 10/03/2024 |
5 | Clene to Present at Upcoming October Conferences | 10/09/2024 |
6 | Acquisition by Jacobovitz Shalom of 30000 shares of Clene at 0.37 subject to Rule 16b-3 | 10/10/2024 |
7 | Clene Inc. Sees Large Growth in Short Interest | 10/16/2024 |
8 | IBN Coverage Clene Set to Discuss Lead Candidate Biomarker With FDA Leadership | 10/25/2024 |
9 | Clene Inc Q3 2024 Earnings EPS of -1.22 Beats Estimates, Revenue at 0. ... | 11/13/2024 |
10 | ARMISTICE CAPITAL, LLC Acquires New Stake in Clene Inc | 11/15/2024 |
11 | Clene shares hold Buy rating as analyst sees FDA decision impacting time to market | 11/22/2024 |
| Begin Period Cash Flow | 18.4 M |
Clene |
Clene Relative Risk vs. Return Landscape
If you would invest 559.00 in Clene Inc on August 25, 2024 and sell it today you would lose (142.00) from holding Clene Inc or give up 25.4% of portfolio value over 90 days. Clene Inc is currently does not generate positive expected returns and assumes 5.7814% risk (volatility on return distribution) over the 90 days horizon. In different words, 51% of stocks are less volatile than Clene, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Clene Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Clene's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Clene Inc, and traders can use it to determine the average amount a Clene's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0504
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CLNN |
Estimated Market Risk
| 5.78 actual daily | 51 51% of assets are less volatile |
Expected Return
| -0.29 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Clene is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Clene by adding Clene to a well-diversified portfolio.
Clene Fundamentals Growth
Clene Stock prices reflect investors' perceptions of the future prospects and financial health of Clene, and Clene fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Clene Stock performance.
| Return On Equity | -2.9 | ||||
| Return On Asset | -0.42 | ||||
| Operating Margin | (81.22) % | ||||
| Current Valuation | 41.51 M | ||||
| Shares Outstanding | 7.98 M | ||||
| Price To Earning | 4.09 X | ||||
| Price To Book | 7.83 X | ||||
| Price To Sales | 75.28 X | ||||
| Revenue | 654 K | ||||
| Gross Profit | 447 K | ||||
| EBITDA | (43.24 M) | ||||
| Net Income | (49.5 M) | ||||
| Cash And Equivalents | 16.23 M | ||||
| Cash Per Share | 0.22 X | ||||
| Total Debt | 32.16 M | ||||
| Current Ratio | 3.49 X | ||||
| Book Value Per Share | 2.08 X | ||||
| Cash Flow From Operations | (30.17 M) | ||||
| Earnings Per Share | (5.29) X | ||||
| Market Capitalization | 33.28 M | ||||
| Total Asset | 52.34 M | ||||
| Retained Earnings | (242.72 M) | ||||
| Working Capital | 13.52 M | ||||
About Clene Performance
By examining Clene's fundamental ratios, stakeholders can obtain critical insights into Clene's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Clene is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 111.61 | 106.03 | |
| Return On Tangible Assets | (0.95) | (0.99) | |
| Return On Capital Employed | (1.50) | (1.58) | |
| Return On Assets | (0.95) | (0.99) | |
| Return On Equity | (3.70) | (3.88) |
Things to note about Clene Inc performance evaluation
Checking the ongoing alerts about Clene for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Clene Inc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Clene Inc generated a negative expected return over the last 90 days | |
| Clene Inc has high historical volatility and very poor performance | |
| Clene Inc has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 654 K. Net Loss for the year was (49.5 M) with profit before overhead, payroll, taxes, and interest of 447 K. | |
| Clene Inc currently holds about 16.23 M in cash with (30.17 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.22. | |
| Clene Inc has a frail financial position based on the latest SEC disclosures | |
| Roughly 28.0% of the company shares are held by company insiders | |
| Latest headline from investing.com: Clene shares hold Buy rating as analyst sees FDA decision impacting time to market |
- Analyzing Clene's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Clene's stock is overvalued or undervalued compared to its peers.
- Examining Clene's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Clene's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Clene's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Clene's stock. These opinions can provide insight into Clene's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Clene Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Clene. If investors know Clene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Clene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.614 | Earnings Share (5.29) | Revenue Per Share 0.069 | Quarterly Revenue Growth (0.66) | Return On Assets (0.42) |
The market value of Clene Inc is measured differently than its book value, which is the value of Clene that is recorded on the company's balance sheet. Investors also form their own opinion of Clene's value that differs from its market value or its book value, called intrinsic value, which is Clene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Clene's market value can be influenced by many factors that don't directly affect Clene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Clene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Clene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Clene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.